Patents by Inventor Renate Stahn

Renate Stahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF HUMAN CELLS OF MYELOID LEUKAEMIA ORIGIN FOR EXPRESSION OF ANTIBODIES
    Publication number: 20190359731
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Application
    Filed: April 5, 2019
    Publication date: November 28, 2019
    Inventors: Steffen GOLETZ, Antje DANIELCZYK, Hans BAUMEISTER, Renate STAHN, Anja LOEFFLER, Lars STOECKL
  • Use of human cells of myeloid leukemia origin for expression of antibodies
    Patent number: 10280230
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: May 7, 2019
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Hans Baumeister, Renate Stahn, Anja Loeffler, Lars Stoeckl
  • Recognition molecules for the treatment and detection of tumors
    Patent number: 9845361
    Abstract: The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising said recognition molecules, methods for the production of said recognition molecules, and to the use of said recognition molecules in the diagnosis and therapy of tumor diseases.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: December 19, 2017
    Assignee: GLYCOTOPE GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Renate Stahn, Uwe Karsten
  • Tumor-specific recognition molecules
    Patent number: 9345794
    Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: May 24, 2016
    Assignee: Glycotype GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen
  • USE OF HUMAN CELLS OF MYELOID LEUKAEMIA ORIGIN FOR EXPRESSION OF ANTIBODIES
    Publication number: 20150368363
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Application
    Filed: May 4, 2015
    Publication date: December 24, 2015
    Inventors: Steffen GOLETZ, Antje DANIELCZYK, Hans BAUMEISTER, Renate STAHN, Anja LOEFFLER, Lars STOECKL
  • MUC1 antibodies
    Patent number: 9217038
    Abstract: The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: December 22, 2015
    Assignee: GLYCOTOPE GMBH
    Inventors: Steffen Goletz, Antje Danielczyk, Renate Stahn, Uwe Karsten
  • Use of human cells of myeloid leukaemia origin for expression of antibodies
    Patent number: 9051356
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: June 9, 2015
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Hans Baumeister, Renate Stahn, Anja Löffler, Lars Stöckl
  • RECOGNITION MOLECULES FOR THE TREATMENT AND DETECTION OF TUMORS
    Publication number: 20150005474
    Abstract: The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising said recognition molecules, methods for the production of said recognition molecules, and to the use of said recognition molecules in the diagnosis and therapy of tumor diseases.
    Type: Application
    Filed: June 26, 2014
    Publication date: January 1, 2015
    Inventors: Steffen Goletz, Antje Danielczyk, Renate Stahn, Uwe Karsten
  • Recognition molecules for the treatment and detection of tumors
    Patent number: 8779102
    Abstract: The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising such recognition molecules, methods for the production of such recognition molecules, and to the use of such recognition molecules in the diagnosis and therapy of tumor diseases.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: July 15, 2014
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Renate Stahn, Uwe Karsten
  • TUMOR-SPECIFIC RECOGNITION MOLECULES
    Publication number: 20140099259
    Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.
    Type: Application
    Filed: December 10, 2013
    Publication date: April 10, 2014
    Applicant: Glycotope GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen
  • Tumor-specific recognition molecules
    Patent number: 8617846
    Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: December 31, 2013
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen
  • TUMOR-SPECIFIC RECOGNITION MOLECULES
    Publication number: 20120149877
    Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.
    Type: Application
    Filed: November 22, 2011
    Publication date: June 14, 2012
    Applicant: GLYCOTOPE GMBH
    Inventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen
  • MUC1 ANTIBODIES
    Publication number: 20120128676
    Abstract: The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer.
    Type: Application
    Filed: July 30, 2010
    Publication date: May 24, 2012
    Applicant: GLYCOTOPE GMBH
    Inventors: Steffen Goletz, Antje Danielczyk, Renate Stahn, Uwe Karsten
  • Tumor-specific recognition molecules
    Patent number: 8088357
    Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.
    Type: Grant
    Filed: December 1, 2003
    Date of Patent: January 3, 2012
    Assignee: Nemod Biotherapeutics GmbH & Co. KG
    Inventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen
  • USE OF HUMAN CELLS OF MYELOID LEUKAEMIA ORIGIN FOR EXPRESSION OF ANTIBODIES
    Publication number: 20100028947
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Application
    Filed: September 10, 2007
    Publication date: February 4, 2010
    Inventors: Steffen Goletz, Antje Danielczyk, Hans Baumeister, Renate Stahn, Anja Löffler, Lars Stöckl
  • Recognition molecules for the treatment and detection of tumours
    Publication number: 20060292643
    Abstract: The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising said recognition molecules, methods for the production of said recognition molecules, and to the use of said recognition molecules in the diagnosis and therapy of tumor diseases.
    Type: Application
    Filed: January 23, 2004
    Publication date: December 28, 2006
    Inventors: Steffen Goletz, Antje Danielczyk, Renate Stahn, Uwe Karsten
  • Tumor-specific recognition molecules
    Publication number: 20060251668
    Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.
    Type: Application
    Filed: December 1, 2003
    Publication date: November 9, 2006
    Inventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Christensen
  • Use of selectin-binding pregnancy proteins, liposomes, native mucin fragments and mimetic compounds for the treatment and prophylaxis inflammatory diseases, for preventing metastatic spread and for the prophylaxis of tumour diseases
    Publication number: 20040191303
    Abstract: A selectin-binding active agents in the form of gestation proteins or fragments thereof, of liposomes which include Ca-binding compounds, of mucin fragments obtained or derived from native sources, or of mimicry compounds which imitate sialylated Lewis type carbohydrate structures (sLe), or combinations thereof, in the treatment and prophylaxis of diseases, in the course of which inflammatory processes are involved, such as autoimmune diseases, transplantations and arteriosclerosis. Inflammatory diseases in the meaning of the invention can be those of infectious or non-infectious nature. The active agents provide partial or complete prevention of tumor metastasizing, wherein administration of the active agents can be prophylactic, or can be effected in association with e.g. operative removal of a primary tumor or during a biopsy. The above active agents are used in the prophylaxis of tumor diseases.
    Type: Application
    Filed: September 24, 2003
    Publication date: September 30, 2004
    Inventors: Renate Stahn, Steffen Goletz, Udo Jeschke, Iduna Fichtner, Reinhard Zeisig